| Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma | Frank Vinluan | 10/13/20 | San Diego |
| Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More | Frank Vinluan | 10/09/20 | National |
| In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug | Frank Vinluan | 10/08/20 | National |
| BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting | Editors | 10/08/20 | Boston |
| Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More | Frank Vinluan | 10/02/20 | National |
| With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug | Frank Vinluan | 09/30/20 | New York |
| Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward | Frank Vinluan | 09/25/20 | Europe |
| Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More | Frank Vinluan | 09/25/20 | National |
| Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders | Frank Vinluan | 09/23/20 | San Diego |
| Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week | Editors | 09/21/20 | Boston |
| Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal | Frank Vinluan | 09/21/20 | San Francisco |
| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D | Frank Vinluan | 09/17/20 | Boston |
| Moderna CMO Talks COVID-19 Vaccine at the Xcelerate Keynote Series | Editors | 09/16/20 | Boston |
| Join Xconomy Next Week at the Virtual Xcelerate Keynote Series at Biotech Week Boston | Editors | 09/14/20 | Boston |
| Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | Frank Vinluan | 09/11/20 | National |
| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs | Frank Vinluan | 09/02/20 | Seattle |
| Early Bird Sale for Xcelerate at Biotech Week Boston Ends This Friday | Editors | 08/31/20 | Boston |
| Akcea Therapeutics Is Returning to Parent Ionis Pharma in $500M Buyout | Frank Vinluan | 08/31/20 | Boston |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases | Frank Vinluan | 08/26/20 | Boston |
| Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout | Sarah de Crescenzo | 08/26/20 | San Diego |
| FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines | Sarah de Crescenzo | 08/24/20 | National |
| Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More | Sarah de Crescenzo | 08/21/20 | National |
| Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts | Sarah de Crescenzo | 08/20/20 | National |
| Patient Death in Poseida Prostate Cancer Study Prompts Clinical Hold | Sarah de Crescenzo | 08/18/20 | San Diego |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup | Sarah de Crescenzo | 08/11/20 | San Diego |
| Bayer Boosts Women’s Health Drug Pipeline, Paying $425M for KaNDy | Frank Vinluan | 08/11/20 | Europe |
